ERBB2 and breast cancer: Although large studies on intratumor TILs and prognosis are still scarce, using more than 2000 prospectively collected samples from a phase III adjuvant randomized breast cancer trial, Loi, et al reported that intratumoral TILs were associated with better disease-free and overall survival in TNBC, whereas they were not in ER-positive/HER2-negative or HER2-positive subtypes.2 Furthermore, Denkert et al also reported statistically significant linear relationships between the number of intratumoral TILs and improved outcomes in TNBC, which was also confirmed by Loi et al1,2